Table 3.
Multistate outcome analysis of treatment analysis of time to transition from one stage of amyotrophic lateral sclerosis to the next
| 50 mg/day riluzole | 100 mg/day riluzole | 200 mg/day riluzole | Placebo | ||
|---|---|---|---|---|---|
| Stage transition | |||||
| 2–3 | 109 (99–118) | 70 (60–81) | 100 (89–110) | 82 (72–91) | |
| 3–4 | 38 (29–48) | 52 (43–61) | 30 (23–37) | 69 (61–78) | |
| 4–5 | 207 (195–219) | 234 (222–246) | 226 (215–237) | 198 (186–209) | |
Data are the mean number of days (95% CI), presented by treatment group.